Tips for Mobile App Privacy Compliance
Safeguards against Data Security Breaches (Part Two)
Safeguards against Data Security Breaches (Part One)
For more than four decades, Fenwick & West has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.
Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.
From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.
At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.
Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:
- Nearly 15 percent of Fenwick partners named America's Leading Lawyers for Business by Chambers USA and Chambers Global
- Selected as a "Go-To" law firm by in-house legal departments at Fortune 500 companies in Corporate Counsel magazine
- Named to The National Law Journal's inaugural "Intellectual Property Hot List" for outstanding patent, copyright, trademark and IP litigation services
We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.
Read more about our commitment to sustainability and cleantech
At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.
Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041
650.988.8500
San Francisco Office
555 California Street
12th Floor
San Francisco, CA 94104
415.875.2300
Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101
206.389.4510
|
Dr. Shuster is a partner in Fenwick & West's Intellectual Property Practice and is co-chair of the firm's Life Sciences Group.
Dr. Shuster has legal and technical experience representing companies in biotechnology and high technology areas that include protein and nucleic acid chemistry, clean tech, high resolution protein structures, proteomics, genomics, combinatorial peptide libraries, vaccine development for viral and autoimmune disorders, transdermal drug delivery systems, liposomal drug formulations as well as microfluidics devices.
Dr. Shuster received his undergraduate education at Brandeis University, graduating with a B.A. in Biophysics. He recieved his J.D. from the University of San Francisco School of Law and his Ph.D. from Columbia University's Department of Physiology and Molecular Biophysics. While at Columbia he worked with Professor Eric Kandel as part of a team focused on discovery of mechanisms by which short term memories are stored, work for which Professor Kandel was awarded the Nobel Prize in Medicine in 2000. Dr. Shuster pursued his interests in ion channel biophysics and protein structure, first as a Markey post-doctoral fellow at UCSF's Department of Biochemistry & Biophysics, and then as a research biochemist studying neuronal mechanisms of pain transduction in UCSF's Department of Medicine.
Currently, Dr. Shuster is a co-instructor of "A Life Scientist's Guide to Intellectual Property" at UCSF, and regularly lectures about intellectual property law subjects. He is past chair of the Intellectual Property section of the Barrister's Club of San Francisco. Dr. Shuster was named one of Top 25 Biotech Lawyers in California in 2011 and one of the Top 25 Intellectual Property Portfolio Managers in 2009 and 2012 by the Daily Journal. He was also recognized as a "Life Sciences Star" for his outstanding patent work in Euromoney's LMG Life Sciences 2012.
Dr. Shuster has published numerous scientific papers in peer-reviewed journals as well as articles on biotechnology patent law. Representative technologies for which he's written and prosecuted patent applications include genomics, proteomics, bioinformatics, vaccines, microfluidic devices, drug delivery methods and microarrays.
Organization and Community Participation
- American Bar Association
- California Bar Association
- San Francisco Bar Association
- San Francisco Intellectual Property Law Association
- Biophysical Society
Articles
- Justices Consider Patent Process for Personalized Medicine Industry, Michael Shuster, Daily Journal, February 15, 2012
- A Comparison of US and EU Biosimilars Regimes, Michael Shuster & Pauline Farmer-Koppenol, January 6, 2012.
- Classen v. Biogen Idec et al. – The Latest Installment in the Patent-Eligibility Arena, Pauline Farmer-Koppenol & Michael Shuster, October 6, 2011
- Silicon Valley News Radio Interview (Podcast), Michael Shuster, KLIV, October 5, 2011
- Patenting Personalized Medicine Inventions after Myriad, Pauline Farmer-Koppenol & Michael Shuster, August 29, 2011
- First to File in the Unpredictable Arts: Change in Law Requires Balancing of Competing Interests, Nicholas Hurt & Michael Shuster, Daily Journal, August 5, 2011
- Getting the Prescription Right for Patenting Personalized Medicine Innovations, Michael Shuster & Pauline Farmer-Koppenol, iPFrontline Magazine, May 2011
- Biotech in the Wake of 'Bilski', Michael Shuster & Pauline Farmer-Koppenol, The Recorder, July 2010
- Patent Strategy for Personalized Medicine in Light of Bilski, Michael Shuster & Pauline Farmer-Koppenol, July 2010
- Of Babies and Bathwater The Impact of In Re Bilski on Life Science Patents, Michael Shuster & Juleen Konkel, 1 Hastings Science and Technology Law Journal 153, Summer 2009
- An Unclear Diagnosis, Michael Shuster & Juleen Konkel Daily Journal, June 2009
- Protecting Patents for Personalized Medicine, Michael Shuster & Pauline Farmer-Koppenol BioPharm International, September 2008
- Observations on Recent Developments in Patent Law: Is the Generic Claim Turning Into an Endangered Species?, Michael J. Shuster, Pauline Farmer-Koppenol & H. Thomas Anderson Jr. Burrill Report Personalized Medicine, November, 2007
- Planning for the other shoe to drop - Future echoes of LabCorp v. Metabolite, Michael J. Shuster & H. Thomas Anderson Jr. Burrill Report Personalized Medicine, November, 2006
- Responding to the Avian Flu Threat: Balancing Risks and Rewards, Michael J. Shuster, BioPharm International, February 1, 2006
- Managing Innovation: University-industry partnerships and the licensing of the Harvard mouse, Sasha Blaug, Colleen Chien & Michael J. Shuster Nature Biotechnology, Vol. 22, No. 6 (June 2004)
- Altering Patent Suit Proof Burden Would Chill Innovation, Michael J. Shuster, Daniel Flamm & Sasha Blaug, Washington Legal Foundation, April 16, 2004
- Enzo Biochem v. Gen-Probe: Complying with the written description requirement under U.S. patent law, Nature Biotechnology, January, 2003
- Protecting Rights to Early-Stage Technology, Michael J. Shuster, Henry Su & Sasha Blaug, Nature Biotechnology, June, 2003
Presentations
- Supreme Court View on Prometheus Case, Personalized Medicine World Conference (PMWC), January 23, 2012
- Consumer Protection or Government Intrusion: Is Regulation appropriate? Is it different in Europe? Japan? Are companies moving away from “betting the company” on the FDA?, Burrill Personalized Medicine Conference, October 4, 2011
- AMA Speaker Series - Life Sciences, Asia America MultiTechnology Association, June 26, 2007
- Life Science Entrepreneurs' Forum, FountainBlue Consulting Services, September 18, 2006
- A Life Scientist's Guide to Intellectual Property: Drafting Patent Applications, UCSF, April 25, 2006
- A Life Scientist'' Guide to Intellectual Property: Life and Death of a Patent, UCSF, April 18, 2006
- 6th Advanced Forum on Biotech Patents: Constructing The Plan For The Future, American Conference Institute, February 16, 2006
- Radio Interview on World Talk Radio's Biotech Today, September 24, 2003
|
